Laurie Burlingame is a partner in the firm’s nationally recognized Life Sciences group. She represents private and public companies across the spectrum of the life sciences industry, including pharmaceuticals, medical devices, diagnostics and biological materials. Ms. Burlingame also represents leading venture capital firms focused on the life sciences industry in connection with their portfolio company investments.
Ms. Burlingame often serves as outside general counsel to her clients, closely advising management teams and boards of directors on a wide variety of matters throughout the company’s life cycle, including formation and founder issues, venture capital financings, public offerings, mergers and acquisitions, licensing transactions, strategic collaborations, commercial transactions, corporate governance and other general corporate matters.
Experience
A selection of Ms. Burlingame’s recent client representations includes:
Representative Matters
- SpringWorks Therapeutics, Inc. in its 2019 initial public offering
- Axcella Health Inc. in its 2019 initial public offering in its $60.1 million follow-on offering and subsequent $35 million “at the market” offering
- Kaleido Biosciences Inc. in its 2019 initial public offering in its $35.6 million follow-on offering
- Akero Therapeutics Inc. in its 2019 initial public offering
- Scholar Rock Holding Corporation in its 2018 initial public offering and follow-on public offering
- Neon Therapeutics, Inc. in its 2018 initial public offering
- Voyager Therapeutics, Inc. in its 2016 initial public offering
- Celyad S.A. in its 2015 U.S. initial public offering
- Blueprint Medicines Corporation in its 2015 initial public offering
- Sage Therapeutics, Inc. in its 2014initial public offering and follow-on public offerings
- Zafgen, Inc. in its 2014 initial public offering and several of its follow-on public offerings
- Cerevance, LLC in its $65 million Series B Preferred Unit financing
- Xilio Therapeutics, LLC in its $100 million Series B Preferred Unit financing
- Admirx Inc. in its $43 million Series A Preferred Stock financing
- SpringWorks Therapeutics, Inc. in its $125 million Series B Preferred Stock financing
- Gemini Therapeutics, Inc. in its Series B Preferred Stock financing and Series A Preferred Stock financing
- Akero Therapeutics, Inc. in its Series B Preferred Stock financing and Series A Preferred Stock financing
- Axcella Health in its Series E Preferred Stock financing
- Kaleido Biosciences Inc. in its $101 Series B Preferred Stock financing
- Cadent Therapeutics, Inc. in its $40 million Series B Preferred Stock financing
- Neon Therapeutics, Inc. in its formation, $55 million Series A Preferred Stock financing and $70 million Series B Preferred Stock financing
- Voyager Therapeutics, Inc. in its formation, $47 million Series A Preferred Stock financing and $60 million Series B Preferred Stock financing
- Mevion Medical Systems, Inc. in connection with its up to $200 million Series F Preferred Stock financing
- SetPoint Medical Corporation in connection with its $15 million Series C-1 Preferred Stock financing,$27 million Series C Preferred Stock financing and $35 million Series C-2 Preferred Stock financing
- Scholar Rock Holding Corporation in its Series C Preferred Stock financing, Series B Preferred Unit financing and its Series A Preferred Unit financing
- RaNA Therapeutics, LLC in its Series B Preferred Unit financing
- iWalk, Inc. in its Series E Preferred Stock financing
- NinePoint Medical, Inc. in its $34 million Series B Preferred Stock financing and Series C Preferred Stock financing
- Cerevance, LLC in its Series A Preferred Unit financing
- Accelerator IV-New York Corporation and Accelerator IV-Seattle Corporation in their formation and funding
- AgTech Accelerator Corporation in its formation and initial funding
- Flexion Therapeutics in its licensing agreement with HK Tainuo for the development and commercialization of Flexion’s product ZILRETTA® in Greater China
- Mevion Medical Systems, Inc. in connection with its merger transaction
- Acetylon Pharmaceuticals, Inc. in its up to $1.7 billion collaboration and buyout option transaction with Celgene Corporation, and subsequent Share Purchase Transaction with Celgene Corporation
- Abide Therapeutics, Inc. in its collaboration and buyout option transaction with Celgene Corporation
- ZOLL Medical Corporation in its acquisition of Advanced Circulatory Systems, Inc.
- ZOLL Medical Corporation in its acquisition of the assets of Impact Instrumentation, Inc.
- Nimbus Therapeutics, Inc. in connection with its innovative collaborations with Monsanto and Shire Plc
- BionX Medical Technologies, Inc. in connection with its merger with Ottobock
Professional Experience
Ms. Burlingame is a member of Women Entrepreneurs in Science and Technology (WEST) and through the firm is a member of the Massachusetts Biotechnology Council (MBC) and MassMEDIC. She is also a member of the American and Boston Bar Associations.
Ms. Burlingame is a key contributor to Goodwin’s Founders Workbench, an online resource for start-ups, emerging companies and the entrepreneurial community. Ms. Burlingame has served as a workshop speaker and advisor to the Boston Pipeline Angels for the past several years and has provided advice to start-up companies and entrepreneurs through participation in events and office hours held by Harvard University and M.I.T.
Ms. Burlingame is a member of the Board of Directors of Sitters Without Borders, a member of the Board of Directors of Tailored for Success and a member of the Board of Directors of Mass AWIS.
Credentials
Education
JD2006
Harvard Law School
Masters of Business Admin2003
Clark University
Artium MagisterGraduate School of Arts and Sciences2002
Harvard University
BA1999
Wellesley College
(summa cum laude, major in biology and psychology)
Admissions
Bars
- Massachusetts
- U.S. Patent and Trademark Office (USPTO)
Recognition & Awards
Ms. Burlingame has been the recipient of a writing award from the Boston Patent Law Association.